Skip to content
Screener

Intangibles (Net) at other companies

Scilex Holding Company logo
Scilex Holding CompanySCLX
$59.81M+90.2%
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$319.49M-15.2%
Bioventus logo
BioventusBVS
$351.05M-9.3%
Organon logo
OrganonOGN
$1.1B-22.4%
Dogwood Therapeutics logo
Dogwood TherapeuticsDWTX
$67.83M+3.1%
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
$43.8K-99.7%

Segments

By product

See full
Azstarys$627.52M
Jornay PM$482.01M-14.8%
Symproic and other$42.5M-14.6%
Symproic$38.86M-15.8%
Belbuca$37.7M-66.7%

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$955.82M-16.0%
Enterprise value$810.41M-19.5%
P/E20×-11.4×
P/S1.2×-0.4×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851
Line itemJune 30, 2026 / CostJune 30, 2026 / Accumulated AmortizationJune 30, 2026 / Carrying AmountDecember 31, 2025 / CostDecember 31, 2025 / Accumulated AmortizationDecember 31, 2025 / Carrying Amount
Jornay PM$635,000$(152,986)$482,014$635,000$(111,072)$523,928
Azstarys635,000(7,480)627,520
Belbuca360,000(322,305)37,695360,000(284,607)75,393
Nucynta Products521,170(521,170)521,170(493,478)27,692
Symproic70,000(31,145)38,85570,000(27,503)42,497
Total intangible assets$2,221,170$(1,035,086)$1,186,084$1,586,170$(916,660)$669,510

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s intangibles (net)?
Collegium Pharmaceutical, Inc. (COLL) reported intangibles (net) of $1.19B in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s intangibles (net) changed year-over-year?
Collegium Pharmaceutical, Inc.'s intangibles (net) increased by 52.0% year-over-year, from $780.46M to $1.19B.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s intangibles (net)?
Over 4 years (2021 to 2025), Collegium Pharmaceutical, Inc.'s intangibles (net) has grown at a 25.6% compound annual growth rate (CAGR), from $268.72M to $669.51M.
What does intangibles (net) mean?
Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.

Ask your AI about Collegium Pharmaceutical, Inc.'s intangibles (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude